2014年慢性病毒性肝炎临床诊疗进展*

doi:10.3969/j.issn.1672-5069.2015.01.004

摘要/Abstract

Key words: Viral hepatitis, Chronic hepatitis B, Chronic hepatitis C, Antiviral therapy

吴迪, 宁琴. 2014年慢性病毒性肝炎临床诊疗进展^*[J]. 实用肝脏病杂志, 2015, 18(1): 10-14.

Wu Di, Ning Qin. 2014 update on the diagnosis and treatment of chronic viral hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 10-14.

[1] McBride G. Hepatitis B virus-induced liver cancer in Asian Americans:a preventable disease. J Natl Cancer Inst,2008,100（8）:528-529.
[2] Liang XF,Bi SL,Yang WZ,et a1. Reprint of: Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination.Vaccine,2013,27（31 Suppl 9）:J21-28.
[3] Liang XF,Bi SL,Yang WZ,et a1. Evaluation of the impact of hepatitis B vaccination among children born between 1992 and 2005 in China. J Infect Dis,2009,200（1）:39-47.
[4] Brunetto MR. A new role for an old marker,HBsAg. J Hepatol,2010,52（4）:475-477.
[5] Guyen T,Thompson AJ,Bowden S,et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol,2010,52（4）:508-513.
[6] Ning Q,Han M,Sun Y,et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:A randomised open-label trial （OSST trial）. J Hepatol,2014,61（4）:777-784.
[7] Chen CH,Lu SN,Hung CH,et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol,2014,61（3）:515-522.
[8] Gordon SC,Krastev Z,Horban A,et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology,2013,58（2）:505-513.
[9] Rijckborst V,Hansen BE,Ferenci P,et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol,2012,56（5）:1006-10011.
[10] Rijckborst V,Hansen BE,Cakaloglu Y,et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology,2010,52（2）:454-461.
[11] Thursz M,Yee L,Khakoo S. Understanding the host genetics of chronic hepatitis B and C. Semin Liver Dis,2011,31（2）:115-127.
[12] de Groen RA1,Mcphee F,Friborg J,et al. Endogenous IFNλ in viral hepatitis patients. J Interferon Cytokine Res,2014,34（7）:552-556.
[13] Takkenberg RB,Menting S,Beld MG. Validation of a sensitive and specific real-time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients. Methods Mol Biol,2012,903:113-128.
[14] Seeger C,Mason W. Hepatitis B virus biology. Microbiol Mol Biol Rev,2000,64（1）:51-68.
[15] Hoofnagle JH,Dibisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med,1997,336（5）:347-356.
[16] Brouwer WP,Xie Q,Sonneveld MJ,et al. Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B:A multicentre randomized trial（ARES study）. Hepatology,2014[Epub ahead of print].
[17] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[18] Guo W,Wu D,Wang P,et al. A prospective,open-label cohort study comparing the efficacy,safety and drug resistance of entecavir monotherapy versus de novo combination of lamivudine and adefovir dipivoxil in naive HBeAg-positive chronic hepatitis B patients with high HBV viral load（The Climber Study）:a preliminary analysis. AASLD. 2014.
[19] Yan H,Zhong G,Xu G,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012,13;1.
[20] Volz T,Allweiss L,Ben MBarek M,et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol, 2013,58（5）:861-867.
[21] Nkongolo S,Ni Y,Lempp FA,et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol,2014,60（4）:723-731.
[22] Carroll D. Genome engineering with zinc-finger nucleases. Genetics,2011,188（4）:773-782.
[23] Lucifora J,Xia Y,Reisinger F,et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science,2014,343（6176）,1221-1228.
[24] Lanford RE,Guerra B,Chavez D,et al. GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144（7）:1508-1517.
[25] Dadmanesh M,Ghorban K,Hassanshahi G,et al. Current information concerning association of IL-12 and hepatitis B infection. Clin Lab, 2014,60（2）:185-191.
[26] Chen HM,Liu HL,Yang YC,et al. Serum IL-21 levels associated with chronic hepatitis B and hepatitis B-related liver failure. Exp Ther Med,2014,7（4）:1013-1019.
[27] Kapoor R,Kottilil S. Strategies to eliminate HBV infection. Future Virol,2014,9（6）:565-585.
[28] Cova L. Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection. Curr Gene Ther,2014,14（3）:149-160.
[29] Fletcher SP,Delaney WE 4th. New therapeutic targets and drugs for the treatment of chronic hepatitis B. Semin Liver Dis,2013,33（2）:130-137.
[30] 中华医学会肝病学分会、中华医学会传染病与寄生虫病学分会. 丙型肝炎防治指南.中华传染病杂志,2004,22（2）:131-136 .
[31] Park SH,Park CK,Lee JW,et al. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea:a multi-center,retrospective observational study. Gut Liver,2012,6（1）:98-106.
[32] Shimada N1,Toyoda H,Tsubota A,et al. Baseline factors and very early viral response （week 1） for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol,2014,49（11）:1485-1494.
[33] Lin CL,Kao JH. The clinical implications of hepatitis B virus genotype:recent advances. J Gastroenterol Hepatol,2011,26（Suppl 1）:123-130.
[34] Cobsen IM,Brown RS Jr,Freilich B,et a1.Pegintefferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients:a randomized trial. Hepatology,2007,46（4）:971-981.
[35] 慢性丙型肝炎抗病毒治疗专家委员会. 慢性丙型肝炎抗病毒治疗专家共识. 中华实验和临床感染病杂志,2009,3（3）:59-64.
[36] Grebely J,Petoumenos K,Hellard M,et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology,2010,52（4）:1216-1224.
[37] McCarthy JJ,Li JH,Thompson A,et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology,2010,138（7）:2307-2314.
[38] Sarrazin C,Susser S,Doehring A,et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol,2011,54（3）:1099-1106.
[39] Rauch A,Kutalik Z,Descombes P,et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study. Gastroenterology, 2010,138（4）:1338-1345.
[40] European Association of the Study of the Liver. 2011 European association of the study of the liver hepatitis C virus clinical practice guidelines. Liver Int,2012,32（1）:2-8.
[41] Hayes NC,Chayama K. Emerging treatments for chronic hepatitis C. J Formos Med Assoc,2014,1-12[Epub ahead of print].
[42] Marc GG,David RN,Doris BS,et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases. J Hepatol,2011,54（4）:1433-1444.

2014年慢性病毒性肝炎临床诊疗进展^*

2014 update on the diagnosis and treatment of chronic viral hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[11]	韩美玲, 陈平. 肝硬化血小板减少患者的抗病毒治疗[J]. 实用肝脏病杂志, 2019, 22(4): 466-469.
[12]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[13]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[14]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[15]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.